No Data
J.P. Morgan Upgrades Alnylam Pharmaceuticals(ALNY.US) to Buy Rating, Raises Target Price to $328
Alnylam (ALNY.US) siRNA therapy Amvuttra ( vutrisiran ) has received approval for expanded indications to treat adult patients with ATTR-CM.
Recently, the USA FDA approved Alnylam Pharmaceuticals' (ALNY.US) siRNA therapy Amvuttra (vutrisiran) for the expanded indication to treat adult patients with ATTR-CM.
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals Presents 'Convincing Multi-Billion Dollar Opportunity': Analyst Upgrades Stock
Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?
Carnival To Rally Around 48%? Here Are 10 Top Analyst Forecasts For Monday
siti_kasim 8⃣4⃣ : hi
Brawl Stars : hi hi
siti_kasim 8⃣4⃣ : good morning
71816004 : somewhat good news